Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab for Refractory Opportunistic Infections in HIV/AIDS
NCT07579247Phase 2Not yet recruiting
- Start
- May 2026
- Primary completion
- Dec 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in opportunistic infection. Planned start May 2026; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
opportunistic infection
Beyond the preview
Go deeper on NCT07579247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07579247.